The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Open accessAbstract
The Cancer Genome Atlas Network recently cataloged recurrent genomic abnormalities in glioblastoma multiforme (GBM). We describe a robust gene expression-based molecular classification of GBM into Proneural, Neural, Classical, and Mesenchymal subtypes and integrate multidimensional genomic data to establish patterns of somatic mutations and DNA copy number. Aberrations and gene expression of EGFR, NF1, and PDGFRA/IDH1 each define the Classical, Mesenchymal, and Proneural subtypes, respectively. Gene signatures of normal brain cell types show a strong relationship between subtypes and different neural lineages. Additionally, response to aggressive therapy differs by subtype, with the greatest benefit in the Classical subtype and no benefit in the Proneural subtype. We provide a framework that unifies transcriptomic and genomic dimensions for GBM molecular stratification with important implications for future studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“High-throughput genomic, epigenomic, and transcriptomic profiling of glioblastoma cells revealed three main subtypes harboring distinct molecular and phenotypic landscapes that affect response to the therapy and clinical outcome: mesenchymal, proneural, and classical subtypes.96,97,98,99,100”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although PDGFRA is a frequent target of genomic amplification and gain-of-function mutations in glioblastoma (15%), such alterations are rare in IDH mutant tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Nonetheless, IDH mutant gliomas strongly express PDGFRA (Fig. 2b), and share the proneural transcriptional program characteristic of PDGFRA-amplified tumors23,24.”
From Insulator dysfunction and oncogene activation in IDH mutant gliomas (2016) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prevalence of p53 mutations differs in the different GBM molecular subtypes (proneural, mesenchymal, neural and classical) (54%, 32%, 21% and 0%, respectively) [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Crucially, the levels of miR-128-3p forms can also differ depending on the genetic and molecular background, as they correlated with the glioblastoma subtypes, with the most reduced expression in the most aggressive mesenchymal one.96,113”
From MiR-128-3p – a gray eminence of the human central nervous system (2024) · cites this paper as [96]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“For example, upregulation of PDGFRA, platelet-derived growth factor receptor alpha, is a hallmark of the proneural subtype [15].”
From The p53 Pathway in Glioblastoma (2018) · cites this paper as [15]
In the citing paper
“While glioblastoma is the most common malignant primary brain tumor26–28, it is still classified as a “rare” disease, as its incidence rate (i.e., 3/100,000 people) is substantially lower than the rare disease definition rate (i.e., <10/100,000 people)24.”
From Federated learning enables big data for rare cancer boundary detection (2022) · cites this paper as [27]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Silhouettes: A graphical aid to the interpretation and validation of cluster analysis
Rousseeuw, P. J. (1987) · Journal of Computational and Applied Mathematics · doi:10.1016/0377-0427(87)90125-7 · Cited by 21,392
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F. Z., Miled, S. B., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,785
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
DAVID: Database for Annotation, Visualization, and Integrated Discovery
Dennis, G., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C., & Lempicki, R. A. (2003) · Genome Biology · doi:10.1186/gb-2003-4-5-p3 · Cited by 9,327
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
The Cancer Genome Atlas Research Network (2008) · Nature · doi:10.1038/nature07385 · Cited by 7,735
MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma
Hegi, M. E., Diserens, A.-C., Gorlia, T., Hamou, M.-F., de Tribolet, N., Weller, M., Kros, J. M., Hainfellner, J. A., Mason, W., Mariani, L., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043331 · Cited by 7,405
Epithelial–mesenchymal transitions in tumour progression
Thiery, J. P. (2002) · Nature reviews. Cancer · doi:10.1038/nrc822 · Cited by 6,767
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., Schinzel, A. C., Sandy, P., Meylan, E., Scholl, C., et al. (2009) · Nature · doi:10.1038/nature08460 · Cited by 3,922
Self-citation
Cited by
Sorted by citations
Items 201–300 of 1,022
Bady, P., Sciuscio, D., Diserens, A., Bloch, J., van den Bent, M. J., Marosi, C., Dietrich, P.-Y., Weller, M., Mariani, L., Heppner, F. L., et al. (2012) · Acta Neuropathologica · doi:10.1007/s00401-012-1016-2 · Cited by 351
Boron neutron capture therapy: Current status and future perspectives
Dymova, M. A., Taskaev, S. Y., Richter, V. A., & Kuligina, E. V. (2020) · 癌症：英文版 · doi:10.1002/cac2.12089 · Cited by 344
Chen, W. W., Balaj, L., Liau, L. M., Samuels, M. L., Kotsopoulos, S. K., Maguire, C. A., LoGuidice, L., Soto, H., Garrett, M. C., Zhu, L. D., et al. (2013) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2013.28 · Cited by 349
Han, J., Chu, J., Chan, W. K., Zhang, J., Wang, Y., Cohen, J. B., Victor, A. R., Meisen, W. H., Kim, S.-H., Grandi, P., et al. (2015) · Scientific Reports · doi:10.1038/srep11483 · Cited by 346
Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma
Chen, P., Zhao, D., Li, J., Liang, X., Li, J., Chang, A. H., Henry, V. K., Lan, Z., Spring, D. J., Rao, G., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.003 · Cited by 344
Akers, J. C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S. C., Kalinina, J., Hua, W., Kesari, S., Mao, Y. Q., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0078115 · Cited by 347
Pathway-based personalized analysis of cancer
Drier, Y., Sheffer, M., & Domany, E. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1219651110 · Cited by 336
Making sense of cancer genomic dataPreprint
Chin, L., Hahn, W. C., Getz, G. A., & Meyerson, M. M. (2011) · Genes & Development · doi:10.1101/gad.2017311 · Cited by 346
Self-citationKlughammer, J., Kiesel, B., Roetzer-Pejrimovsky, T., Fortelny, N., Nemc, A., Nenning, K., Furtner, J., Sheffield, N. C., Datlinger, P., Peter, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0156-x · Cited by 336
Xie, Y., Bergström, T., Jiang, Y., Johansson, P., Marinescu, V. D., Lindberg, N., Segerman, A., Wicher, G., Niklasson, M., Baskaran, S., et al. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.08.026 · Cited by 329
Kim, I. S., Gao, Y., Welte, T., Wang, H., Liu, J., Janghorban, M., Sheng, K., Niu, Y., Goldstein, A., Zhao, N., et al. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0373-7 · Cited by 340
Mimeault, M., & Batra, S. K. (2013) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.12004 · Cited by 339
TSGene: a web resource for tumor suppressor genes
Zhao, M., Sun, J., & Zhao, Z. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks937 · Cited by 328
Walter, V., Yin, X., Wilkerson, M. D., Cabanski, C. R., Zhao, N., Du, Y., Ang, M., Hayward, M. C., Salazar, A. H., Hoadley, K. A., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056823 · Cited by 332
Self-citationThe bromodomain protein Brd4 insulates chromatin from DNA damage signalling
Floyd, S., Pacold, M. E., Huang, Q., Clarke, S. M., Lam, F. C., Cannell, I. G., Bryson, B. D., Rameseder, J., Lee, M. J., Blake, E. J., et al. (2013) · Nature · doi:10.1038/nature12147 · Cited by 338
Reátegui, E., van der Vos, K. E., Lai, C. P., Zeinali, M., Atai, N. A., Aldikacti, B., Floyd, F. P., Khankhel, A. H., Thapar, V., Hochberg, F. H., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02261-1 · Cited by 335
Hematogenous dissemination of glioblastoma multiforme
Müller, C., Holtschmidt, J., Auer, M., Heitzer, E., Lamszus, K., Schulte, A., Matschke, J., Langer-Freitag, S., Gasch, C., Stoupiec, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3009095 · Cited by 334
The Glioma Stem Cell Model in the Era of Single-Cell Genomics
Suvà, M. L., & Tirosh, I. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.04.001 · Cited by 334
Glioblastoma multiforme: State of the art and future therapeutics
Harter, D., Wilson, T., & Karajannis, M. A. (2014) · Surgical Neurology International · doi:10.4103/2152-7806.132138 · Cited by 354
Zhao, W., He, X., Hoadley, K. A., Parker, J. S., Hayes, D. N., & Perou, C. M. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-419 · Cited by 338
Self-citationDiagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives
Szopa, W., Burley, T. A., Krämer-Marek, G., & Kaspera, W. (2017) · BioMed Research International · doi:10.1155/2017/8013575 · Cited by 334
The Role of Hypoxia in Glioblastoma Invasion
Monteiro, A. R., Hill, R., Pilkington, G. J., & Madureira, P. A. (2017) · Cells · doi:10.3390/cells6040045 · Cited by 333
Pavlyukov, M. S., Yu, H., Bastola, S., Minata, M., Shender, V. О., Lee, Y., Zhang, S., Wang, J., Komarova, S. V., Wang, J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.05.012 · Cited by 326
deCarvalho, A. C., Kim, H., Poisson, L., Winn, M. E., Mueller, C., Cherba, D., Koeman, J. M., Seth, S., Protopopov, A. I., Felicella, M. M., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0105-0 · Cited by 305
Self-citationPope, W. B., Prins, R. M., Albert Thomas, M., Nagarajan, R., Yen, K. E., Bittinger, M. A., Salamon, N., Chou, A. P., Yong, W. H., Soto, H., et al. (2012) · Journal of Neuro-Oncology · doi:10.1007/s11060-011-0737-8 · Cited by 318
Glioblastoma Multiforme: Exploratory Radiogenomic Analysis by Using Quantitative Image Features
Gevaert, O., Mitchell, L. A., Achrol, A. S., Xu, J., Echegaray, S., Steinberg, G. K., Cheshier, S. H., Napel, S., Zaharchuk, G., & Plevritis, S. K. (2014) · Radiology · doi:10.1148/radiol.14131731 · Cited by 319
Cancer genomics: one cell at a time
Navin, N. E. (2014) · Genome biology · doi:10.1186/s13059-014-0452-9 · Cited by 318
Precision Medicine: Disease Subtyping and Tailored Treatment
Wang, R. C., & Wang, Z. (2023) · Cancers · doi:10.3390/cancers15153837 · Cited by 354
Tissue mechanics regulate brain development, homeostasis and disease
Barnes, J. M., Przybyla, L., & Weaver, V. M. (2017) · Journal of Cell Science · doi:10.1242/jcs.191742 · Cited by 344
Spatiotemporal Evolution of the Primary Glioblastoma Genome
Kim, J., Lee, I., Cho, H. J., Park, C., Jung, Y.-S., Kim, Y., Nam, S. H., Kim, B. S., Johnson, M. D., Kong, D., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.013 · Cited by 328
Richards, L. M., Whitley, O., MacLeod, G. D. A. H., Cavalli, F. M. G., Coutinho, F. J., Jaramillo, J. E., Svergun, N., Riverin, M., Croucher, D. C., Kushida, M. M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-020-00154-9 · Cited by 320
van der Vos, K. E., Abels, E. R., Zhang, X., Lai, C., Carrizosa, E., Oakley, D., Prabhakar, S., Mardini, O., Crommentuijn, M. H. W., Skog, J., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/nov244 · Cited by 315
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma
Yabo, Y. A., Niclou, S. P., & Golebiewska, A. (2021) · Neuro-Oncology · doi:10.1093/neuonc/noab269 · Cited by 341
EGFR heterogeneity and implications for therapeutic intervention in glioblastoma
Eskilsson, E., Røsland, G. V., Solecki, G. M., Wang, Q., Harter, P. N., Graziani, G., Verhaak, R. G. W., Winkler, F., Bjerkvig, R., & Miletić, H. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox191 · Cited by 313
Self-citationWeller, M., Weber, R. G., Willscher, E., Riehmer, V., Hentschel, B., Kreuz, M., Felsberg, J., Beyer, U., Loeffler‐Wirth, H., Kaulich, K., et al. (2015) · Acta Neuropathologica · doi:10.1007/s00401-015-1409-0 · Cited by 312
Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
Beier, D., Schulz, J. B., & Beier, C. P. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-128 · Cited by 308
Diagnostic and therapeutic avenues for glioblastoma: no longer a dead end?
Tanaka, S., Louis, D. N., Curry, W. T., Batchelor, T. T., & Dietrich, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.204 · Cited by 317
Current trends in the surgical management and treatment of adult glioblastoma.
Young, R. M., Jamshidi, A. M., Davis, G., & Sherman, J. H. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.05.10 · Cited by 332
Glioblastoma at the crossroads: current understanding and future therapeutic horizons
Singh, S., Dey, D., Barik, D., Mohapatra, I., Kim, S., Sharma, M., Prasad, S., Wang, P., Singh, A. R., & Singh, G. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02299-4 · Cited by 373
Glioma CpG island methylator phenotype (G-CIMP): biological and clinical implications
Malta, T. M., de Souza, C. F., Sabedot, T. S., Silva, T. C., Mosella, M. S., Kalkanis, S. N., Snyder, J., Castro, A. V. B., & Noushmehr, H. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox183 · Cited by 302
–Omic and Electronic Health Record Big Data Analytics for Precision Medicine
Wu, P.-Y., Cheng, C., Kaddi, C. D., Venugopalan, J., Hoffman, R., & Wang, M. D. (2016) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2016.2573285 · Cited by 317
The NF1 somatic mutational landscape in sporadic human cancers
Philpott, C., Tovell, H., Frayling, I. M., Cooper, D. N., & Upadhyaya, M. (2017) · Human Genomics · doi:10.1186/s40246-017-0109-3 · Cited by 318
Consensus on the role of human cytomegalovirus in glioblastoma
Dziurzynski, K., Chang, S. M., Heimberger, A. B., Kalejta, R. F., Dallas, S. R. M., Smit, M. J., Soroceanu, L., Cobbs, C., & Symposium, T. H. A. G. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nor227 · Cited by 318
Joseph, J. V., Conroy, S., Pavlov, K., Sontakke, P., Tomar, T., Eggens‐Meijer, E., Balasubramaniyan, V., Wagemakers, M., den Dunnen, W. F. A., & Kruyt, F. A. E. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.01.010 · Cited by 315
Isella, C., Brundu, F. G., Bellomo, S. E., Galimi, F., Zanella, E. R., Porporato, R., Petti, C., Fiori, A., Orzan, F., Senetta, R., et al. (2017) · Nature Communications · doi:10.1038/ncomms15107 · Cited by 304
Inhibition of BET Bromodomain Targets Genetically Diverse Glioblastoma
Cheng, Z., Gong, Y., Ma, Y., Lu, K., Lu, X., Pierce, L. A., Thompson, R. C., Müller, S., Knapp, S., & Wang, J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3066 · Cited by 305
Akalay, I., Janji, B., Hasmim, M., Noman, M. Z., André, F., de Crémoux, P., Bertheau, P., Badoual, C., Vielh, P. R., Larsen, A. K., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2432 · Cited by 314
A Combined Preclinical Therapy of Cannabinoids and Temozolomide against Glioma
Torres, S., Lorente, M., Rodríguez-Fornés, F., Hernández‐Tiedra, S., Salazar‐Roa, M., García-Taboada, E., Barcia, J. A., Guzmán, M., & Velasco, G. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0688 · Cited by 309
Macyszyn, L. J., Akbari, H., Pisapia, J. M., Da, X., Attiah, M. A., Pigrish, V., Bi, Y., Pal, S., Davuluri, R. V., Roccograndi, L., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov127 · Cited by 300
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
Yen, K. E., Bittinger, M. A., Su, S. M., & Fantin, V. R. (2010) · Oncogene · doi:10.1038/onc.2010.444 · Cited by 296
Gill, B. J. A., Pisapia, D. J., Malone, H. R., Goldstein, H. E., Lei, L., Sonabend, A. M., Yun, J. J., Samanamud, J. L., Sims, J. S., Banu, M. A., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1405839111 · Cited by 303
Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling
Zuckermann, M., Hovestadt, V., Knobbe-Thomsen, C. B., Zapatka, M., Northcott, P. A., Schramm, K., Belic, J., Jones, D. T. W., Tschida, B., Moriarity, B., et al. (2015) · Nature Communications · doi:10.1038/ncomms8391 · Cited by 283
Cancer epigenetics: linking basic biology to clinical medicine
Tsai, H.-C., & Baylin, S. B. (2011) · Cell Research · doi:10.1038/cr.2011.24 · Cited by 303
A review of glioblastoma immunotherapy
Medikonda, R. T., Dunn, G. P., Rahman, M., Fecci, P. E., & Lim, M. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03448-1 · Cited by 307
Sandmann, T., Bourgon, R., Garcia, J., Li, C., Cloughesy, T. F., Chinot, O. L., Wick, W., Nishikawa, R., Mason, W. P., Henriksson, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.5005 · Cited by 302
Intratumoral heterogeneity in glioblastoma: don't forget the peritumoral brain zone
D, J.-M. L. M., Clavreul, A., & Meneï, P. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov119 · Cited by 303
Chow, L. M. L., Endersby, R., Zhu, X., Rankin, S. L., Qu, C., Zhang, J., Broniscer, A., Ellison, D. W., & Baker, S. J. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.039 · Cited by 303
The role of glioma stem cells in chemotherapy resistance and glioblastoma multiforme recurrence
Auffinger, B., Spencer, D. A., Pytel, P., Ahmed, A. U., & Lesniak, M. S. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1051968 · Cited by 301
Agnihotri, S., & Zadeh, G. M. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nov125 · Cited by 302
Hombach‐Klonisch, S., Mehrpour, M., Shojaei, S., Harlos, C. H., Pitz, M. W., Hamaï, A., Siemianowicz, K., Likus, W., Wiecheć, E., Toyota, B. D., et al. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.017 · Cited by 298
Epithelial-mesenchymal transition in glioblastoma progression
Iwadate, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4113 · Cited by 297
Johanns, T. M., Miller, C. A., Dorward, I. G., Tsien, C. I., Chang, E. F., Perry, A., Uppaluri, R., Ferguson, C., Schmidt, R. E., Dahiya, S. M., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0575 · Cited by 297
Self-citationGlioma: experimental models and reality
Lenting, K., Verhaak, R. G. W., ter Laan, M., Wesseling, P., & Leenders, W. P. J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1671-4 · Cited by 300
Self-citationChen, P., Fan, Y., Man, T., Hung, Y., Lau, C. C., & Wong, S. T. C. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-s18-s1 · Cited by 288
Sattiraju, A., Kang, S., Giotti, B., Chen, Z., Marallano, V. J., Brusco, C., Ramakrishnan, A., Shen, L., Tsankov, A. M., Hambardzumyan, D., et al. (2023) · Immunity · doi:10.1016/j.immuni.2023.06.017 · Cited by 306
EGFR Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing
Francis, J. M., Zhang, C.-Z., Maire, C. L., Jung, J., Manzo, V. E., Adalsteinsson, V. A., Homer, H., Haidar, S., Blumenstiel, B., Pedamallu, C. S., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0879 · Cited by 287
Self-citationCancer heterogeneity—a multifaceted view
Melo, F. D. S. E., Vermeulen, L., Fessler, E., & Medema, J. P. (2013) · EMBO Reports · doi:10.1038/embor.2013.92 · Cited by 287
Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma
Wang, X., Guo, G., Guan, H., Yu, Y., Lu, J., & Yu, J. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1085-3 · Cited by 292
The neurobiology of gliomas: from cell biology to the development of therapeutic approaches
Westphal, M., & Lamszus, K. (2011) · Nature reviews. Neuroscience · doi:10.1038/nrn3060 · Cited by 293
Advances in Brain Tumor Surgery for Glioblastoma in Adults
Lara-Velazquez, M. A., Al‐kharboosh, R., Jeanneret, S., Vazquez-Ramos, C. A., Mahato, D., Tavanaiepour, D., Rahmathulla, G., & Quiñones‐Hinojosa, A. (2017) · Brain Sciences · doi:10.3390/brainsci7120166 · Cited by 284
Pouyan, A., Ghorbanlo, M., Eslami, M., Jahanshahi, M., Ziaei, E., Salami, A., Mokhtari, K., Shahpasand, K., Farahani, N., Meybodi, T. E., et al. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02267-0 · Cited by 338
Molecular diagnostics of gliomas: state of the art
Riemenschneider, M. J., Jeuken, J. W. M., Wesseling, P., & Reifenberger, G. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0736-4 · Cited by 295
Smith, B. D., Kaufman, M. D., Lu, W.-P., Gupta, A., Leary, C. B., Wise, S., Rutkoski, T. J., Ahn, Y. M., Al-Ani, G., Bulfer, S. L., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.04.006 · Cited by 283
Tan, T. Z., Miow, Q. H., Huang, R. Y., Wong, M. K., Ye, J., Lau, J. A., Wu, M., Hadi, L. A., Soong, R., Choolani, M. A., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201823 · Cited by 280
A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data
Mo, Q., Shen, R., Guo, C., Vannucci, M., Chan, K. S., & Hilsenbeck, S. G. (2017) · Biostatistics · doi:10.1093/biostatistics/kxx017 · Cited by 294
Computational deconvolution: extracting cell type-specific information from heterogeneous samples
Shen-Orr, S. S., & Gaujoux, R. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.09.015 · Cited by 287
Neutrophils Promote the Malignant Glioma Phenotype through S100A4
Liang, J., Piao, Y., Holmes, L., Fuller, G. N., Henry, V. K., Tiao, N., & de Groot, J. F. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1279 · Cited by 277
Wilkerson, M. D., Yin, X., Hoadley, K. A., Liu, Y., Hayward, M. C., Cabanski, C. R., Muldrew, K. L., Miller, C. R., Randell, S. H., Socinski, M. A., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0199 · Cited by 280
Self-citationWhole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma
Kannan, K. S., Inagaki, A., Silber, J., Gorovets, D. J., Zhang, J., Kastenhuber, E. R., Heguy, A., Petrini, J. H. J., Chan, T. A.-T., & Huse, J. T. (2012) · Oncotarget · doi:10.18632/oncotarget.689 · Cited by 283
Pathological and Molecular Features of Glioblastoma and Its Peritumoral Tissue
D’Alessio, A., Proietti, G., Sica, G., & Scicchitano, B. M. (2019) · Cancers · doi:10.3390/cancers11040469 · Cited by 289
Rheinbay, E., Suvà, M. L., Gillespie, S. M., Wakimoto, H., Patel, A. P., Shahid, M., Oksuz, O., Rabkin, S. D., Martuza, R. L., Rivera, M. N., et al. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.04.021 · Cited by 283
Spatiotemporal genomic architecture informs precision oncology in glioblastoma
Lee, J., Wang, J., Sa, J. K., Ladewig, E., Lee, H., Lee, I., Kang, H. J., Rosenbloom, D. I. S., Cámara, P. G., Liu, Z., et al. (2017) · Nature Genetics · doi:10.1038/ng.3806 · Cited by 284
WNT signaling in glioblastoma and therapeutic opportunities
Lee, Y., Lee, J., Ahn, S. H., Lee, J., & Nam, D. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.140 · Cited by 278
Antunes, A. R. P., Scheyltjens, I., Duerinck, J., Neyns, B., Movahedi, K., & Ginderachter, J. A. V. (2020) · eLife · doi:10.7554/elife.52176 · Cited by 279
Itakura, H., Achrol, A. S., Mitchell, L. A., Loya, J. J., Liu, T. T., Westbroek, E. M., Feroze, A. H., Rodriguez, S., Echegaray, S., Azad, T. D., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7582 · Cited by 270
Agnihotri, S., Burrell, K. E., Wolf, A., Jalali, S., Hawkins, C. E., Rutka, J. T., & Zadeh, G. M. (2012) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-012-0203-0 · Cited by 293
Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma
Zhou, J., Patel, T., Sirianni, R. W., Strohbehn, G. W., Zheng, M., Duong, N. T., Schafbauer, T., Huttner, A. J., Huang, Y. H., Carson, R. E., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1304504110 · Cited by 277
Molecular Mechanisms of Treatment Resistance in Glioblastoma
Ou, A. C., Yung, W. K. A., & Majd, N. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010351 · Cited by 283
Cancer transcriptome profiling at the juncture of clinical translation
Cieslik, M. P., & Chinnaiyan, A. M. (2017) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 266
Cell of Origin for Malignant Gliomas and Its Implication in Therapeutic DevelopmentPreprint
Zong, H., Parada, L. F., & Baker, S. J. (2015) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a020610 · Cited by 281
Mathematical Modeling of PDGF-Driven Glioblastoma Reveals Optimized Radiation Dosing Schedules
Leder, K., Pitter, K. L., LaPlant, Q. C., Hambardzumyan, D., Ross, B. D., Chan, T. A.-T., Holland, E. C., & Michor, F. (2014) · Cell · doi:10.1016/j.cell.2013.12.029 · Cited by 269
Kickingereder, P., GOETZ, M. A., Muschelli, J., Wick, A., Neuberger, U., Shinohara, R. T., Sill, M., Nowosielski, M., Schlemmer, H.-P., Radbruch, A., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0702 · Cited by 268
Galavotti, S., Bartesaghi, S., Faccenda, D., Shaked-Rabi, M., Sanzone, S., McEvoy, A. W., Dinsdale, D. D., Condorelli, F., Brandner, S., Campanella, M., et al. (2012) · Oncogene · doi:10.1038/onc.2012.111 · Cited by 278
Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme
Zinn, P. O., Majadan, B., Sathyan, P., Singh, S. K., Majumder, S., Jolesz, F. A., & Colen, R. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025451 · Cited by 269
Aberrant Signaling Pathways in Glioma
Nakada, M., Kita, D., Watanabe, T., Hayashi, Y., Teng, L., Pyko, I. V., & Hamada, J. (2011) · Cancers · doi:10.3390/cancers3033242 · Cited by 277
Targeting adaptive glioblastoma: an overview of proliferation and invasion
Xie, Q. R., Mittal, S., & Berens, M. E. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou147 · Cited by 270
Killela, P. J., Pirozzi, C. J., Healy, P. N., Reitman, Z. J., Lipp, E., Rasheed, B. A., Yang, R. R., Diplas, B. H., Wang, Z., Greer, P. K., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.1765 · Cited by 270
Tumor Cell Invasion in Glioblastoma
Vollmann‐Zwerenz, A., Leidgens, V., Feliciello, G., Klein, C. A., & Hau, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21061932 · Cited by 270
Using the molecular classification of glioblastoma to inform personalized treatment
Olar, A., & Aldape, K. (2013) · The Journal of Pathology · doi:10.1002/path.4282 · Cited by 278
Griveau, A., Seano, G., Shelton, S. J., Kupp, R., Jahangiri, A., Obernier, K., Krishnan, S., Lindberg, O. R., Yuen, T. J., Tien, A., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.020 · Cited by 264
Metadata
- Authors
- Verhaak, R. G. W., Hoadley, K. A., Purdom, E., Wang, V., Qi, Y., Wilkerson, M. D., Miller, C. R., Ding, L., Golub, T., Mesirov, J. P., Alexe, G., Lawrence, M., O'Kelly, M., Tamayo, P., Weir, B. A., Gabriel, S., Winckler, W., Gupta, S., Jakkula, L., Feiler, H. S., Hodgson, J. G., James, C. D., Sarkaria, J. N., Brennan, C., Kahn, A., Spellman, P. T., Wilson, R. K., Speed, T. P., Gray, J. W., Meyerson, M., Getz, G., Perou, C. M., & Hayes, D. N.
- Affiliations
- Broad Institute (US)
- University of North Carolina at Chapel Hill (US)
- University of California, Berkeley (US)
- Washington University in St. Louis (US)
- Lawrence Berkeley National Laboratory (US)
- University of California, San Francisco (US)
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- SRA International (United States) (US)
- Walter and Eliza Hall Institute of Medical Research (AU)
- Corresponding author
- Hayes, D. Neil
- ORCID
- Verhaak, Roel G.W.
- Hoadley, Katherine A.
- Purdom, Elizabeth
- Wang, Victoria
- Qi, Yuan
- Wilkerson, Matthew D.
- Miller, C. Ryan
- Ding, Li
- Golub, Todd
- Mesirov, Jill P.
- Lawrence, Michael
- Tamayo, Pablo
- Gabriel, Stacey
- Winckler, Wendy
- Gupta, Supriya
- Feiler, Heidi S.
- Hodgson, J. Graeme
- James, C. David
- Sarkaria, Jann N.
- Brennan, Cameron
- Spellman, Paul T.
- Wilson, Richard K.
- Speed, Terence P.
- Gray, Joe W.
- Meyerson, Matthew
- Getz, Gad
- Perou, Charles M.
- Hayes, D. Neil
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 17
- Issue
- 1
- Pages
- 98-110
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2818769
- OpenAlex
- W2161289668
- Cited by
- 7,575
- References
- 52
- Citations by year
- 2026: 312 · 2025: 399 · 2024: 451 · 2023: 551 · 2022: 523 · 2021: 697 · 2020: 593 · 2019: 493 · 2018: 482 · 2017: 522 · 2016: 502 · 2015: 455 · 2014: 459 · 2013: 406 · 2012: 379
- FWCI
- 159.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion, public-domain)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Department of Energy
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273)
- National Cancer Institute (CA097257, L30 CA104183, U24CA126554, R01CA127716, CA108961, U24CA126546, U24CA126543, U24CA126563, U24CA126544, U24CA143867, U24CA143848, P50CA108961, U24CA126551, CA127716, P50 CA 58223, U24CA126561, P50CA058223, P50CA097257)
- National Institute of Neurological Disorders and Stroke (R01NS049720, NS49720)
- National Institute of Environmental Health Sciences (F30ES019449)
- National Center for Research Resources (RR023248, K12RR023248, UL1RR024992)
- Topics
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Keywords
- glioblastoma, molecular subtypes, proneural subtype, mesenchymal subtype, classical subtype, PDGFRA, IDH1, EGFR, neurofibromatosis type 1, somatic mutations, gene expression signatures, neural lineage, treatment response, molecular stratification
- MeSH terms
- Adult, Aged, Brain Neoplasms, DNA Mutational Analysis, Factor Analysis, Statistical, Glioblastoma, Humans, Isocitrate Dehydrogenase, Middle Aged, Mutation, Neurofibromatosis 1, Prognosis, Gene Expression, Gene Dosage, Oligonucleotide Array Sequence Analysis, Receptor, Platelet-Derived Growth Factor alpha, Gene Expression Profiling, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
